Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Obeticholic acid
DRUG: Bezafibrate 200 MG
DRUG: OCA Placebo
DRUG: Bezafibrate 200 mg Placebo
DRUG: Bezafibrate 400 MG
DRUG: Bezafibrate 400 mg Placebo
DRUG: OCA
DRUG: Bezafibrate

Sponsor

Intercept Pharmaceuticals